Skip to content
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Friday, December 5, 2025
World Today News
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Copyright 2021 - All Right Reserved
Home » pharmaceutical industry » Page 2
Tag:

pharmaceutical industry

News

ADHD medication abuse in schools is a ‘wake-up call’

by Emma Walker – News Editor July 29, 2025
written by Emma Walker – News Editor

Experts emphasize the need to scrutinize school-based strategies for their effectiveness in combating the misuse of stimulant medications. Parents are encouraged to verify that their children’s schools implement secure medication storage and stringent dispensing protocols. Inquiring about the prevalence of misuse within the school, as this data is frequently enough accessible, is also advised.

Families can also play a crucial role by engaging in conversations with their children about how to respond when peers solicit stimulant pills for recreational use or to enhance academic performance.

many young individuals lack a clear response when faced with such requests. Parents can proactively prepare their children by practicing scenarios and equipping them with appropriate phrases to use when approached.

It is essential for parents and guardians to consistently store controlled medications in a secure, locked container. They should also feel empowered to monitor pill counts and address early prescription refills.

Should parents suspect any form of medication misuse, they should promptly consult their child’s prescribing physician. This immediate action can facilitate necessary screening and assessment for the child.

July 29, 2025 0 comments
0 FacebookTwitterPinterestEmail
Business

Illuccix® PSMA-PET Approval Boosts Prostate Cancer Detection in Austria

by Priya Shah – Business Editor July 20, 2025
written by Priya Shah – Business Editor

“`html

Illuccix® (TLX591-CDx) Erhält Zulassung in Österreich für PSMA-PET-Bildgebung bei Prostatakrebs

Wien, Österreich – [Datum der Veröffentlichung] – Telix Pharmaceuticals Limited (Telix) gibt heute die Zulassung von Illuccix® (TLX591-CDx) durch die österreichischen Behörden bekannt. Das innovative PSMA-PET-Bildgebungsmittel ist nun für die Diagnose von Prostatakrebs in Österreich verfügbar.

Die Zulassung von Illuccix® markiert einen bedeutenden fortschritt in der Prostatakrebsdiagnostik und -behandlung. Das Mittel ermöglicht eine präzisere Darstellung des prostataspezifischen Membranantigens (PSMA), das auf Krebszellen exprimiert wird. Dies unterstützt Ärzte bei der genauen Lokalisierung und charakterisierung von Prostatakrebs, was für die Therapieplanung von entscheidender Bedeutung ist.

Die Positronen-Emissions-Tomographie (PET) [1] ist eine fortschrittliche bildgebende Technik, die in Kombination mit spezifischen Radiotracern wie Illuccix® eine detaillierte molekulare Facts liefert. in Österreich wird die Zulassung und Überwachung von Arzneimitteln durch das Österreichische Bundesamt für Sicherheit im Gesundheitswesen (BASG) [2] gewährleistet.

die Bildgebung von prostataspezifischem Membranantigen mit Positronenemissionstomographie [3] hat sich als wertvolles Werkzeug erwiesen, das die Computertomographie (CT) [4] ergänzen oder in bestimmten Fällen ersetzen kann. Aktuelle Leitlinien, wie die der European Association of Urology (EAU) [5] und der european Society for Medical Oncology (ESMO) [5], unterstreichen die Bedeutung von PSMA-PET in der Prostatakrebsbehandlung.

Die Wirksamkeit und Sicherheit von Illuccix® wurden in klinischen Studien, wie der VISION-Studie [6], die von Endocyte, einem Unternehmen von Novartis, gesponsert wurde, evaluiert. Telix stellte Illuccix® für die PSMA-PET-Bildgebung in dieser studie zur Verfügung.

Die globale Krebsstatistik [7] zeigt die hohe Prävalenz von Prostatakrebs, was die Notwendigkeit fortschrittlicher Diagnosewerkzeuge unterstreicht. Telix hat in den letzten Jahren bedeutende Fortschritte in der Entwicklung und Zulassung von PSMA-PET-Bildgebungsmitteln erzielt, wie frühere ASX-Offenlegungen belegen [8, 9, 10, 11, 12].

Die Zulassung in Österreich erweitert die Verfügbarkeit von Illuccix® in Europa, wo das Mittel bereits in mehreren Ländern zugelassen ist, darunter Frankreich, Schweden, Deutschland, Portugal, Griechenland, Tschechische Republik, Belgien, Italien, Dänemark, Irland, Luxemburg, Malta, Niederlande und Norwegen [13]. Die Zulassung durch das deutsche Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) [14] war ein wichtiger Meilenstein in der europäischen Markteinführung.

Telix Pharmaceuticals Limited ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Radiopharmazeutika für die Diagnose und Behandlung von Krebs konzentriert. Mit der Zulassung von Illuccix® in Österreich stärkt Telix seine Position als führender Anbieter von innovativen Lösungen im Bereich der Onkologie.

Über Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited ist ein global agierendes biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von innovativen Radiopharmazeutika für die Diagnose und Behandlung von Krebs spezialisiert hat. Telix verfolgt eine klare Mission, die Lebensqualität von Krebspatienten durch den Einsatz von zielgerichteter Strahlentherapie und fortschrittlicher Bildgebung zu verbessern.

Logo: https

July 20, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Former pharmacist opens wellness shop, promotes natural alternatives

by Dr. Michael Lee – Health Editor July 16, 2025
written by Dr. Michael Lee – Health Editor

Pharmacist Pivots to Proactive Wellness

Former practitioner champions natural remedies for preventative health.

A former pharmacist has launched a health and wellness shop in Mount Pleasant, shifting focus from reactive prescription treatments to natural, proactive approaches to well-being.

A New Direction

Sunday Muniz, proprietor of Family Strong Wellness, established her store in 2021. After decades in pharmaceutical practice, she felt the industry was too focused on treating illnesses rather than preventing them.

“So that is where, when I, as a pharmacist being reactive all the time, I was like, this is not what I wanted to do. I didn’t want to do this. I wanted to be proactive for people.”

—Sunday Muniz, Owner, Family Strong Wellness

Muniz aims to help individuals avoid the need for doctor visits and hospitalizations altogether. Her shop offers minerals, herbs, vitamins, and other natural supplements, promoting an “organic way to just make sure your body’s got the things it needs to get the job done.”

Bridging Medicine’s Gaps

Muniz advocates for integrating natural methods with conventional medicine, viewing prescription drugs as a last resort. She expressed concern over the potential for adverse side effects from medications, which can lead to a cycle of further prescriptions.

“I’m telling you the side effects, but I’m not helping you understand what to do about the side effects, and what we can do to negate the side effects. And the cumulative side effects that happen as soon as you start adding meds on top of meds on top of meds.”

—Sunday Muniz, Owner, Family Strong Wellness

While acknowledging that prescriptions are sometimes unavoidable, particularly for conditions like high blood pressure, Muniz believes her shop can help mitigate side effects. “If we integrated better, oh my gosh, we would just have so many different outcomes for people,” she stated.

Personal Journey Ignites Passion

Muniz’s own experience during a high-risk twin pregnancy, where she felt severely depleted of nutrients, spurred her interest in natural alternatives. She humorously recalled experiencing significant “pregnancy brain,” relying on her husband to complete her thoughts.

Sunday Muniz stands amidst the products at Family Strong Wellness.

Discovering vitamins and minerals that improved her condition without medical intervention proved life-changing. “It just really changed my life,” Muniz shared, a realization that took decades to translate into her career change.

Science-Backed Natural Solutions

Muniz believes that while all medications carry risks and benefits, society has perhaps overemphasized the benefits. Her extensive background in pharmacy and understanding of biochemistry allows her to identify specific vitamins and minerals that can effectively address various health concerns.

The Centers for Disease Control and Prevention (CDC) reports that 6 in 10 adults in the U.S. have a chronic disease, with many linked to lifestyle factors. Muniz’s approach focuses on empowering individuals to manage their health proactively through natural means.

Former pharmacist opens wellness shop to promote natural alternatives to medication

Muniz is dedicated to helping clients find alternative remedies by prioritizing natural solutions, leveraging her pharmaceutical expertise to guide her recommendations.

July 16, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Senate Bill could make it easier to pick up your prescription meds locally | The Latest from WDEL News

by Dr. Michael Lee – Health Editor July 2, 2025
written by Dr. Michael Lee – Health Editor

Delaware Safeguards Medication Access After Rite Aid Closures

In response to nearly 30 Rite Aid stores closing, **Governor Matt Meyer** has signed Senate Bill 180, fortifying residents’ access to necessary medications, especially in times of emergency.

New Powers for Board of Pharmacy

Senate Bill 180 grants the Board of Pharmacy enhanced authority to adjust Delaware’s licensure protocols. These changes will allow the state to prepare more effectively for emergencies, ensuring continuous access to pharmaceuticals.

According to the American Society of Health-System Pharmacists, about 40% of U.S. pharmacists report feeling burned out, underscoring the need for such measures to maintain stable access to care (ASHP).

Meyer stated, “Delawareans deserve 21st-century healthcare, and that includes fast access to quality pharmaceuticals. By allowing out-of-state licensed pharmacists to practice in Delaware during emergencies, we’re taking proactive steps to ensure our residents have uninterrupted access to essential medications.”

Key Provisions of the Bill

The approved bill enables licensed pharmacists from outside Delaware to practice within the state during declared emergencies.

It also empowers the Board of Pharmacy to modernize its regulations, permitting pharmacy technicians to help with prescription transfers.

Additionally, pharmacies can now process faxed prescription transfers for non-controlled substances similarly to original paper prescriptions, provided all necessary information is included.

Legislators Applaud the Measure

Senator Nicole Poore noted the timeliness of the bill: “Senate Bill 180 has been a long time [coming]… the need to modernize the Board of Pharmacy has been exacerbated by the recent closures of Rite Aid,” She also emphasized that Rite Aid filled over 2.5 million prescriptions in Delaware this year, many for Medicaid recipients.

Representative Kam Smith added, “As Delaware communities continue to feel the deep impact of widespread pharmacy closures, we must act quickly. For many families, these pharmacies are more than just a place to fill prescriptions…they are a lifeline.”

Pharmacy Group’s Perspective

Julie Miro Wenger, Executive Director of the Delaware Association of Chain Drug Stores, commented on the changes. She acknowledged that the closures will force many patients to switch pharmacies, increasing demand on remaining locations.

Miro Wenger stated, “These regulatory and legislative changes offer flexibility that will enhance pharmacy operational efficiencies and enhance their ability to meet increased demand for care in communities throughout the state.”

July 2, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Drug Procurement Maelstrom In MOH Triggers Industry Discontent

by Dr. Michael Lee – Health Editor July 2, 2025
written by Dr. Michael Lee – Health Editor

Malaysia’s Medicine Procurement Faces Scrutiny

Delays and pricing decisions spark confusion and frustration among pharmaceutical companies.

Drug procurement processes in **Malaysia** are facing increasing scrutiny, with delays, pricing discrepancies, and transparency concerns creating a challenging environment for both multinational corporations and local manufacturers.

Tender Delays Threaten Drug Supply

Sources within the pharmaceutical industry report that significant delays in the procurement of essential medications at the national level could lead to artificial shortages. These delays stem from bureaucratic hurdles within the Ministry of Health (MOH) rather than supply chain failures.

One area affected by procurement delays involves dialysis treatment for kidney failure. Government hospitals are resorting to local purchase orders (LPOs) to secure supplies, as national tenders have not been initiated. The reliance on LPOs strains hospital budgets and places extra administrative burdens on healthcare professionals.

The procurement process can take six to nine months, further exacerbating potential shortages. Even if a tender were issued immediately, awarding the contract would take months, followed by additional time for suppliers to deliver medications from abroad.

Pricing Discrepancies Raise Questions

Reports indicate that the MOH has, in some instances, procured locally made generic medications at prices significantly higher—100% to 200%—than those of off-patent branded drugs. This has led to questions about the government’s priorities and the transparency of the procurement process.

An industry source questioned whether the government prioritizes local pharmaceutical companies over patient health, stating, “Local manufacturing is an economic priority, not a health care need. Is MOH prioritising the economy or health care?”

Another source added, “There is no level playing field now. You say you want lower prices, but when we give you cheaper, you still don’t want it. So what’s your criteria? You’re not being transparent.”

Transparency Concerns Mount

The MOH’s double supplier mandate, intended to boost medicine security, has also faced criticism, with concerns that tenders aren’t split equitably between generics and innovators. Some industry sources have also raised issues with the Skim Anak Angkat (SAA) and Skim Panel Pembuat Bumiputera (SPPB) programs, alleging that certain companies have won tenders through direct negotiation without open competition.

Compounding these issues, the Ministry of Finance (MOF) has reportedly stopped publishing the value of competing tender bids on the ePerolehan portal, further fueling concerns about transparency within the industry. According to the United Nations Office on Drugs and Crime, transparent procurement processes are vital to ensure fair competition and prevent corruption (UNODC).

“We’re all angry that we can’t see the pricing,” said one industry insider.

New Drug Launches at Risk

The perceived prioritization of local products over imported medications has raised concerns that pharmaceutical MNCs may be disincentivized from launching new drugs in **Malaysia**, potentially limiting access to innovative treatments for patients.

One industry source noted that a major drug maker only launched one product in **Malaysia** in the last five years, compared to 20 in other countries, citing a “lack of transparency and fair practices in tender issues.”

“Companies are already saying they don’t want to launch new drugs in **Malaysia** for the next five years,” the source added.

Percentage of new medicines launched by Asia-Pacific market (of all 460 new medicines launched from 2012 to end of 2021). Graphic from the Pharmaceutical Research and Manufacturers of America (PhRMA).

Data suggests that only 22% of new medicines are available in **Malaysia**. New medicines face nearly a three-year delay after their initial global launch, with a mere 2% launched within the first year.

Local Manufacturers Face Challenges

Local generic manufacturers also express frustration with government procurement practices, citing increasing competition from **China**. Concerns have been raised about the listing of medicines from **China** and **India** on the Approved Product Purchase List (APPL), sold at highly competitive prices.

“Local manufacturers find it very hard to match Chinese drugs,” one source explained, adding that “These Chinese products are winning MOH tenders.”

Balancing Priorities and Transparency

An industry source emphasized that governments must be transparent about the trade-offs they make in medicine procurement, particularly when choosing between prioritizing local industry and securing the most cost-effective medications.

“What the government is really procuring is not a product then; what the government is procuring is security. Therefore, it’s putting a value and a premium. So then they should say it. And that’s okay,” the source stated.

The MOH has stated it is reviewing procurement policies, but declined to comment on specific issues, noting that procurement policy is under the jurisdiction of the MOF.

Kenyataan Media | Garis Panduan Amalan Klinikal (CPG) Rawatan Diabetes Mellitus Jenis 2 Edisi Ke-6

Kementerian Kesihatan Malaysia (KKM) sentiasa komited dalam menyediakan perkhidmatan kesihatan yang terbaik kepada seluruh rakyat Malaysia. pic.twitter.com/dtEoQQt1E0

— KKMPutrajaya (@KKMPutrajaya) February 1, 2024

As **Malaysia** navigates these complex procurement challenges, open dialogue and transparency will be critical to ensuring access to affordable and effective medications for all citizens.

July 2, 2025 0 comments
0 FacebookTwitterPinterestEmail
Technology

German Industry 2025: Alvarez & Marsal Competition Index Revealed

by Rachel Kim – Technology Editor July 1, 2025
written by Rachel Kim – Technology Editor

German Industry competitiveness Plummets Amid Cost Pressures and Innovation Struggles

Table of Contents

  • German Industry competitiveness Plummets Amid Cost Pressures and Innovation Struggles
    • Key Factors Driving the Decline
    • Strategies for Survival: Automation and Relocation
    • The Innovation Imperative
    • Expert Insights
    • Competitive Index of the German Industry 2025: Key Metrics
    • Evergreen Insights: The Broader Context of German Industrial competitiveness
    • Frequently Asked Questions About German Industry Competitiveness
      • What are the main challenges facing german industry competitiveness?
      • What strategies are German companies using to address these challenges?
      • What is the role of government in supporting German industry competitiveness?
      • What are the potential consequences of a continued decline in German industry competitiveness?
      • How can German companies maintain their innovative edge in the face of cost pressures?

Munich, Germany – The competitiveness of German industry is facing a steep decline, particularly within the chemical and pharmaceutical sectors, according to the latest Alvarez & Marsal Competitive Index. The index reveals a significant drop from 20 points in 2024 to a mere 8 points in 2025,signaling a concerning trend for Europe’s largest economy. This decline is attributed primarily to intense cost pressures coupled with the ongoing challenge of maintaining innovative strength.

Key Factors Driving the Decline

The Alvarez & Marsal Competition Index of the German Industry 2025 highlights several critical factors contributing to this downturn. The most prominent is the overwhelming cost pressure faced by German companies. A staggering 77% of top managers surveyed identified cost pressure as a major concern, forcing them to seek countermeasures to stay competitive.

Did You Know? Germany’s chemical industry is the largest in Europe and the fourth largest worldwide, accounting for approximately 6% of the country’s total industrial production [1].

In response to thes pressures,companies are primarily focusing on optimizing supply chain management and raw material procurement. According to the study, 32% of companies have already successfully implemented such optimizations, while 47% are in the process, and 16% are planning to do so.

Strategies for Survival: Automation and Relocation

Beyond supply chain improvements, German companies are also exploring automation technologies and web-based applications to enhance production efficiency. While only 5% have fully implemented these measures, 48% have partially implemented them, and 12% are in the planning stages. However, the most drastic measure under consideration by over two-thirds of companies is the relocation of production facilities abroad to reduce overhead costs and tap into new markets.

Pro Tip: Companies considering relocation should carefully evaluate the long-term implications, including potential impacts on brand reputation and supply chain resilience.

The Innovation Imperative

Despite the focus on cost reduction,German companies recognize the critical importance of maintaining innovative strength. A significant 75% of managers surveyed emphasized innovation as a key factor for competitiveness. To foster innovation, companies are prioritizing strategic partnerships, open innovation initiatives, and the development of customized offerings.

Furthermore,there’s considerable interest in leveraging digital platforms for research and development,and also utilizing artificial intelligence to drive innovation. Though, a concerning trend is that 55% of companies are also considering relocating research and development activities abroad, signaling a potential loss of intellectual capital for Germany.

Expert Insights

“Companies are primarily implementing digital measures aimed at reducing costs or fostering innovation. In the chemical and pharmaceutical industries, this includes automation in production or the use of Digital Twins to simulate production processes,” explains Dr. Frank Jenner, Managing Director and industry expert at Alvarez & Marsal.

He further adds, “In the fight for competitiveness, the German industry has recognized that it cannot solve all problems from within Germany. Relocating production abroad can also help to better address markets in those regions.”

Competitive Index of the German Industry 2025: Key Metrics

Metric 2024 2025
Competitiveness Index (Chemical & Pharmaceutical) 20 8
Companies prioritizing cost optimization N/A 77%
Companies considering relocation of production N/A 66%
Companies prioritizing innovation N/A 75%
Companies considering relocation of R&D N/A 55%

The study involved in-depth interviews with 241 top managers across key industries, evaluating competitiveness on a scale from -100 to +100 points and analyzing the central challenges and strategies of the industry.

Did you Know? The German government has launched several initiatives to support industry competitiveness, including tax incentives for research and development and funding for infrastructure projects [2].

Will German industries be able to regain their competitive edge? What innovative strategies can be implemented to keep production and R&D within germany?

Evergreen Insights: The Broader Context of German Industrial competitiveness

The decline in German industrial competitiveness is not an isolated event but rather a symptom of broader global economic shifts. Factors such as rising energy costs, increasing regulatory burdens, and growing competition from emerging economies are all contributing to the challenges faced by German companies. Historically, germany has relied on its strong manufacturing base and technological innovation to maintain its competitive advantage. Though,these strengths are now being tested as other countries invest heavily in these areas.

The trend of relocating production and R&D activities abroad is not new, but it is accelerating as companies seek to reduce costs and access new markets. This poses a significant challenge for Germany, as it risks losing its position as a global leader in manufacturing and innovation. To address these challenges, Germany needs to focus on creating a more business-kind environment, investing in education and training, and fostering innovation through collaboration between industry, academia, and government.

Frequently Asked Questions About German Industry Competitiveness

What are the main challenges facing german industry competitiveness?

The primary challenges include high cost pressures, the need for innovation, rising energy costs, increasing regulatory burdens, and growing competition from emerging economies.

What strategies are German companies using to address these challenges?

Companies are focusing on optimizing supply chain management, implementing automation technologies, relocating production facilities, fostering strategic partnerships, and investing in digital platforms for research and development.

What is the role of government in supporting German industry competitiveness?

The government can play a crucial role by creating a more business-friendly environment, investing in education and training, and fostering innovation through collaboration between industry, academia, and government.

What are the potential consequences of a continued decline in German industry competitiveness?

The consequences could include job losses, reduced economic growth, and a loss of Germany’s position as a global leader in manufacturing and innovation.

How can German companies maintain their innovative edge in the face of cost pressures?

By focusing on strategic partnerships, open innovation initiatives, developing customized offerings, and leveraging digital platforms and artificial intelligence for research and development.

Share your thoughts in the comments below and let us know what you think the future holds for german industry!

July 1, 2025 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Search:

Recent Posts

  • Austin homeless encampment sweep cost $830K

    December 5, 2025
  • Lutherans Combat Gender-Based Violence in South Africa

    December 5, 2025
  • Stocks advance, dollar falls as investors eye Fed cut after mild US data

    December 5, 2025
  • Title: Serena Williams: No Return to Tennis, Focus on Exhibition

    December 5, 2025
  • Title: South Korean Robot Stocks Surge on Trump Administration Support

    December 5, 2025

Follow Me

Follow Me
  • Live News Feeds
  • Short Important News
  • Most Important News
  • Headlinez
  • Most Recommended Web Hosting
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Copyright Notice
  • Disclaimer
  • DMCA Policy
  • EDITORIAL TEAM
  • Links
  • Privacy Policy
  • Terms & Conditions

@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com


Back To Top
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com